LARP4B and hepatocellular carcinoma: In conclusion, LARP4B promoted tumorigenicity and progression in HCC, whereas LARP4B knockdown provided beneficial effects of sorafenib treatment, suggesting a potential therapeutic target for the treatment of HCC.